

# Josep Dalmau

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/409806/publications.pdf>

Version: 2024-02-01

421  
papers

53,097  
citations

1531

109  
h-index

1719

219  
g-index

441  
all docs

441  
docs citations

441  
times ranked

15422  
citing authors

#	ARTICLE	IF	CITATIONS
1	A clinical approach to diagnosis of autoimmune encephalitis. <i>Lancet Neurology</i> , The, 2016, 15, 391-404.	4.9	2,782
2	Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. <i>Lancet Neurology</i> , The, 2008, 7, 1091-1098.	4.9	2,696
3	Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. <i>Lancet Neurology</i> , The, 2013, 12, 157-165.	4.9	2,382
4	Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. <i>Annals of Neurology</i> , 2007, 61, 25-36.	2.8	2,166
5	Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. <i>Lancet Neurology</i> , The, 2011, 10, 63-74.	4.9	2,039
6	Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. <i>Annals of Neurology</i> , 2009, 66, 11-18.	2.8	969
7	Cellular and Synaptic Mechanisms of Anti-NMDA Receptor Encephalitis. <i>Journal of Neuroscience</i> , 2010, 30, 5866-5875.	1.7	959
8	Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. <i>Lancet Neurology</i> , The, 2010, 9, 776-785.	4.9	947
9	Antibody-Mediated Encephalitis. <i>New England Journal of Medicine</i> , 2018, 378, 840-851.	13.9	812
10	Antibodies to the GABAB receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. <i>Lancet Neurology</i> , The, 2010, 9, 67-76.	4.9	805
11	Paraneoplastic syndromes of the CNS. <i>Lancet Neurology</i> , The, 2008, 7, 327-340.	4.9	772
12	Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. <i>Lancet Neurology</i> , The, 2014, 13, 167-177.	4.9	758
13	Anti-Hu-Associated Paraneoplastic Encephalomyelitis/Sensory Neuronopathy A Clinical Study of 71 Patients. <i>Medicine (United States)</i> , 1992, 71, 59-72.	0.4	732
14	AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. <i>Annals of Neurology</i> , 2009, 65, 424-434.	2.8	712
15	Clinical analysis of anti-Ma2-associated encephalitis. <i>Brain</i> , 2004, 127, 1831-1844.	3.7	681
16	The Frequency of Autoimmune N-Methyl-D-Aspartate Receptor Encephalitis Surpasses That of Individual Viral Etiologies in Young Individuals Enrolled in the California Encephalitis Project. <i>Clinical Infectious Diseases</i> , 2012, 54, 899-904.	2.9	619
17	Extreme delta brush. <i>Neurology</i> , 2012, 79, 1094-1100.	1.5	614
18	HuD, a paraneoplastic encephalomyelitis antigen, contains RNA-binding domains and is homologous to Elav and sex-lethal. <i>Cell</i> , 1991, 67, 325-333.	13.5	572

#	ARTICLE	IF	CITATIONS
19	Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. <i>Lancet Neurology</i> , The, 2014, 13, 276-286.	4.9	525
20	Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. <i>Annals of Neurology</i> , 2005, 58, 594-604.	2.8	516
21	An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. <i>Lancet Neurology</i> , The, 2019, 18, 1045-1057.	4.9	497
22	Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force. <i>European Journal of Neurology</i> , 2011, 18, 19.	1.7	489
23	A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. <i>Lancet Neurology</i> , The, 2014, 13, 575-586.	4.9	436
24	Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. <i>Brain</i> , 2005, 128, 1764-1777.	3.7	434
25	Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System. <i>Physiological Reviews</i> , 2017, 97, 839-887.	13.1	428
26	Neuronal autoantigensâ€™ pathogenesis, associated disorders and antibody testing. <i>Nature Reviews Neurology</i> , 2012, 8, 380-390.	4.9	424
27	Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. <i>Lancet Neurology</i> , The, 2018, 17, 760-772.	4.9	422
28	Encephalitis and GABA <sub>B</sub> receptor antibodies. <i>Neurology</i> , 2013, 81, 1500-1506.	1.5	412
29	Overlapping demyelinating syndromes and antiâ€™Nâ€™methylâ€™aspartate receptor encephalitis. <i>Annals of Neurology</i> , 2014, 75, 411-428.	2.8	405
30	Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice. <i>Brain</i> , 2015, 138, 94-109.	3.7	391
31	Encephalitis and antibodies to synaptic and neuronal cell surface proteins. <i>Neurology</i> , 2011, 77, 179-189.	1.5	379
32	Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer?A quantitative western blot analysis. <i>Annals of Neurology</i> , 1990, 27, 544-552.	2.8	375
33	Herpes simplex virus encephalitis is a trigger of brain autoimmunity. <i>Annals of Neurology</i> , 2014, 75, 317-323.	2.8	372
34	Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. <i>Annals of Neurology</i> , 2011, 69, 303-311.	2.8	371
35	Pediatric Anti-N-methyl-D-Aspartate Receptor Encephalitisâ€™ Clinical Analysis and Novel Findings in a Series of 20 Patients. <i>Journal of Pediatrics</i> , 2013, 162, 850-856.e2.	0.9	362
36	A Serologic Marker of Paraneoplastic Limbic and Brain-Stem Encephalitis in Patients with Testicular Cancer. <i>New England Journal of Medicine</i> , 1999, 340, 1788-1795.	13.9	356

#	ARTICLE	IF	CITATIONS
37	Frequency and Characteristics of Isolated Psychiatric Episodes in Anti-N-Methyl-D-Aspartate Receptor Encephalitis. <i>JAMA Neurology</i> , 2013, 70, 1133.	4.5	354
38	N-methyl-D-aspartate receptor antibodies in herpes simplex encephalitis. <i>Annals of Neurology</i> , 2012, 72, 902-911.	2.8	343
39	Limbic Encephalitis and Variants: Classification, Diagnosis and Treatment. <i>Neurologist</i> , 2007, 13, 261-271.	0.4	339
40	Antibodies and neuronal autoimmune disorders of the CNS. <i>Journal of Neurology</i> , 2010, 257, 509-517.	1.8	338
41	The clinical spectrum of Caspr2 antibody-associated disease. <i>Neurology</i> , 2016, 87, 521-528.	1.5	327
42	Autoimmune encephalopathies. <i>Annals of the New York Academy of Sciences</i> , 2015, 1338, 94-114.	1.8	322
43	Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	3.1	313
44	Encephalitis and AMPA receptor antibodies. <i>Neurology</i> , 2015, 84, 2403-2412.	1.5	311
45	Encephalitis and antibodies to dipeptidyl-peptidase-like protein 6, a subunit of Kv4.2 potassium channels. <i>Annals of Neurology</i> , 2013, 73, 120-128.	2.8	305
46	Clinical manifestations of the anti-IgLON5 disease. <i>Neurology</i> , 2017, 88, 1736-1743.	1.5	300
47	Cognitive deficits following anti-NMDA receptor encephalitis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 195-198.	0.9	297
48	Evidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratoma. <i>Acta Neuropathologica</i> , 2009, 118, 737-743.	3.9	296
49	Selective Expression of Purkinje-Cell Antigens in Tumor Tissue from Patients with Paraneoplastic Cerebellar Degeneration. <i>New England Journal of Medicine</i> , 1990, 322, 1844-1851.	13.9	287
50	Acute mechanisms underlying antibody effects in anti-N-methyl-D-aspartate receptor encephalitis. <i>Annals of Neurology</i> , 2014, 76, 108-119.	2.8	287
51	Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. <i>Neurology</i> , 2014, 82, 879-886.	1.5	285
52	Anti-LGI1-associated cognitive impairment. <i>Neurology</i> , 2016, 87, 759-765.	1.5	264
53	Investigations in GABA <sub>A</sub> receptor antibody-associated encephalitis. <i>Neurology</i> , 2017, 88, 1012-1020.	1.5	257
54	Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. <i>Annals of Neurology</i> , 2001, 50, 339-348.	2.8	256

#	ARTICLE	IF	CITATIONS
55	Anti-NMDA Receptor Encephalitis Antibody Binding Is Dependent on Amino Acid Identity of a Small Region within the GluN1 Amino Terminal Domain. <i>Journal of Neuroscience</i> , 2012, 32, 11082-11094.	1.7	247
56	A patient with encephalitis associated with NMDA receptor antibodies. <i>Nature Clinical Practice Neurology</i> , 2007, 3, 291-296.	2.7	245
57	Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. <i>Multiple Sclerosis Journal</i> , 2015, 21, 866-874.	1.4	241
58	Autoimmune post-herpes simplex encephalitis of adults and teenagers. <i>Neurology</i> , 2015, 85, 1736-1743.	1.5	226
59	Ma1, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. <i>Brain</i> , 1999, 122, 27-39.	3.7	219
60	Anti-NMDA-receptor encephalitis: A severe, multistage, treatable disorder presenting with psychosis. <i>Journal of Neuroimmunology</i> , 2011, 231, 86-91.	1.1	209
61	Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. <i>Lancet Neurology</i> , The, 2020, 19, 234-246.	4.9	207
62	Immunological characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin's disease. <i>Journal of Neuroimmunology</i> , 1997, 74, 55-61.	1.1	204
63	Update on neurological paraneoplastic syndromes. <i>Current Opinion in Oncology</i> , 2015, 27, 489-495.	1.1	192
64	The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis. <i>Nature Reviews Neurology</i> , 2017, 13, 290-301.	4.9	186
65	Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 535-548.	12.5	186
66	A score that predicts 1-year functional status in patients with anti-NMDA receptor encephalitis. <i>Neurology</i> , 2019, 92, e244-e252.	1.5	183
67	Glycine Receptor Autoimmune Spectrum With Stiff-Man Syndrome Phenotype. <i>JAMA Neurology</i> , 2013, 70, 44.	4.5	180
68	Autoimmune Encephalitis in Children. <i>Journal of Child Neurology</i> , 2012, 27, 1460-1469.	0.7	178
69	NMDA receptor encephalitis and other antibody-mediated disorders of the synapse. <i>Neurology</i> , 2016, 87, 2471-2482.	1.5	178
70	Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	178
71	Motor neuron syndromes in cancer patients. <i>Annals of Neurology</i> , 1997, 41, 722-730.	2.8	175
72	Neuropathological criteria of anti-IgLON5-related tauopathy. <i>Acta Neuropathologica</i> , 2016, 132, 531-543.	3.9	173

#	ARTICLE	IF	CITATIONS
73	Herpes simplex virus-1 encephalitis can trigger anti-NMDA receptor encephalitis: Case report. <i>Neurology</i> , 2013, 81, 1637-1639.	1.5	171
74	DPPX antibody-associated encephalitis. <i>Neurology</i> , 2017, 88, 1340-1348.	1.5	170
75	Late-onset anti-NMDA receptor encephalitis. <i>Neurology</i> , 2013, 81, 1058-1063.	1.5	169
76	Paraneoplastic Neurological Syndromes and Glutamic Acid Decarboxylase Antibodies. <i>JAMA Neurology</i> , 2015, 72, 874.	4.5	169
77	Fluorodeoxyglucose positron emission tomography in anti-N-methyl-D-aspartate receptor encephalitis: distinct pattern of disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 681-686.	0.9	166
78	Anti-NMDA receptor encephalitis, autoimmunity, and psychosis. <i>Schizophrenia Research</i> , 2016, 176, 36-40.	1.1	163
79	Hu antigens: Reactivity with hu antibodies, tumor expression, and major immunogenic sites. <i>Annals of Neurology</i> , 1995, 38, 102-110.	2.8	162
80	Autoimmune encephalitis update. <i>Neuro-Oncology</i> , 2014, 16, 771-778.	0.6	162
81	Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. <i>Cancer</i> , 1995, 75, 99-109.	2.0	159
82	Diagnostic Value of N-methyl-D-aspartate Receptor Antibodies in Women With New-Onset Epilepsy. <i>Archives of Neurology</i> , 2009, 66, 458-64.	4.9	158
83	T-cell receptor analysis in anti-Hu associated paraneoplastic encephalomyelitis. <i>Neurology</i> , 1998, 51, 1146-1150.	1.5	157
84	Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. <i>Annals of Neurology</i> , 1999, 45, 162-167.	2.8	155
85	Interplay between persistent activity and activity-silent dynamics in the prefrontal cortex underlies serial biases in working memory. <i>Nature Neuroscience</i> , 2020, 23, 1016-1024.	7.1	154
86	Clinical and Immunological Features of Opsoclonus-Myoclonus Syndrome in the Era of Neuronal Cell Surface Antibodies. <i>JAMA Neurology</i> , 2016, 73, 417.	4.5	152
87	Autoimmune seizures and epilepsy. <i>Journal of Clinical Investigation</i> , 2019, 129, 926-940.	3.9	152
88	Autoimmune encephalitis as differential diagnosis of infectious encephalitis. <i>Current Opinion in Neurology</i> , 2014, 27, 361-368.	1.8	148
89	Anti-NMDA Receptor Encephalitis in Psychiatry. <i>Current Psychiatry Reviews</i> , 2011, 7, 189-193.	0.9	147
90	Paraneoplastic Neurologic Syndromes: Pathogenesis and Physiopathology. <i>Brain Pathology</i> , 1999, 9, 275-284.	2.1	145

#	ARTICLE	IF	CITATIONS
91	Paraneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas. <i>Blood</i> , 2014, 123, 3230-3238.	0.6	145
92	Investigations on CXCL13 in Anti-N-Methyl-D-Aspartate Receptor Encephalitis. <i>JAMA Neurology</i> , 2015, 72, 180.	4.5	142
93	Paraneoplastic neurological syndromes. <i>Current Opinion in Neurology</i> , 2012, 25, 795-801.	1.8	139
94	Encephalitis with mGluR5 antibodies. <i>Neurology</i> , 2018, 90, e1964-e1972.	1.5	139
95	Autoantigen diversity in the opsoclonus-myoclonus syndrome. <i>Annals of Neurology</i> , 2003, 53, 347-353.	2.8	138
96	Seizures and risk of epilepsy in autoimmune and other inflammatory encephalitis. <i>Current Opinion in Neurology</i> , 2017, 30, 345-353.	1.8	138
97	Tonic seizures: A diagnostic clue of anti-LGI1 encephalitis?. <i>Neurology</i> , 2011, 76, 1355-1357.	1.5	135
98	Clinical and Immunologic Investigations in Patients With Stiff-Person Spectrum Disorder. <i>JAMA Neurology</i> , 2016, 73, 714.	4.5	135
99	EphrinB2 prevents N-methyl-D-aspartate receptor antibody effects on memory and neuroplasticity. <i>Annals of Neurology</i> , 2016, 80, 388-400.	2.8	134
100	GAD antibodies in neurological disorders – insights and challenges. <i>Nature Reviews Neurology</i> , 2020, 16, 353-365.	4.9	134
101	Antineuronal Antibodies in Patients With Neuroblastoma and Paraneoplastic Opsoclonus-Myoclonus. <i>The American Journal of Pediatric Hematology/Oncology</i> , 2000, 22, 315-320.	1.3	129
102	Antibodies to Inhibitory Synaptic Proteins in Neurological Syndromes Associated with Glutamic Acid Decarboxylase Autoimmunity. <i>PLoS ONE</i> , 2015, 10, e0121364.	1.1	127
103	Anti-NMDA receptor encephalitis causing prolonged nonconvulsive status epilepticus. <i>Neurology</i> , 2010, 75, 1480-1482.	1.5	125
104	Cellular plasticity induced by anti-N-methyl-D-glucosaminohydroxymethylisoxazolepropionic acid (AMPA) receptor encephalitis antibodies. <i>Annals of Neurology</i> , 2015, 77, 381-398.	2.8	122
105	Psychiatric Manifestations of Paraneoplastic Disorders. <i>American Journal of Psychiatry</i> , 2010, 167, 1039-1050.	4.0	120
106	Clinical and pathogenic significance of IgG, IgA, and IgM antibodies against the NMDA receptor. <i>Neurology</i> , 2018, 90, e1386-e1394.	1.5	120
107	Antibodies to Aquaporin 4, Myelin-Oligodendrocyte Glycoprotein, and the Glycine Receptor $\beta$ 1 Subunit in Patients With Isolated Optic Neuritis. <i>JAMA Neurology</i> , 2015, 72, 187.	4.5	119
108	Human neurexin-3 antibodies associate with encephalitis and alter synapse development. <i>Neurology</i> , 2016, 86, 2235-2242.	1.5	116

#	ARTICLE	IF	CITATIONS
109	High prevalence of <scp>NMDA</scp> receptor IgA/IgM antibodies in different dementia types. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 822-832.	1.7	114
110	Immunological and pathological study of anti-Ri-associated encephalopathy. <i>Annals of Neurology</i> , 1994, 36, 896-902.	2.8	113
111	Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes. <i>Journal of Neurology</i> , 2016, 263, 1349-1360.	1.8	112
112	LG11 antibodies alter Kv1.1 and AMPA receptors changing synaptic excitability, plasticity and memory. <i>Brain</i> , 2018, 141, 3144-3159.	3.7	112
113	A Post-Transcriptional Regulatory Mechanism Restricts Expression of the Paraneoplastic Cerebellar Degeneration Antigen cdr2 to Immune Privileged Tissues. <i>Journal of Neuroscience</i> , 1997, 17, 1406-1415.	1.7	110
114	Reversible brain atrophy in anti-NMDA receptor encephalitis: a long-term observational study. <i>Journal of Neurology</i> , 2010, 257, 1686-1691.	1.8	106
115	Anti-DPPX encephalitis. <i>Neurology</i> , 2015, 85, 890-897.	1.5	106
116	Mechanisms underlying autoimmune synaptic encephalitis leading to disorders of memory, behavior and cognition: insights from molecular, cellular and synaptic studies. <i>European Journal of Neuroscience</i> , 2010, 32, 298-309.	1.2	104
117	Detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders. <i>Annals of Neurology</i> , 1999, 46, 774-777.	2.8	103
118	Dynamic disorganization of synaptic NMDA receptors triggered by autoantibodies from psychotic patients. <i>Nature Communications</i> , 2017, 8, 1791.	5.8	103
119	In vivo effects of antibodies from patients with anti-NMDA receptor encephalitis: further evidence of synaptic glutamatergic dysfunction. <i>Orphanet Journal of Rare Diseases</i> , 2010, 5, 31.	1.2	102
120	The Emerging Link Between Autoimmune Disorders and Neuropsychiatric Disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2011, 23, 90-97.	0.9	102
121	<scp>NMDAR</scp> encephalitis: passive transfer from man to mouse by a recombinant antibody. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 768-783.	1.7	101
122	Antibody-associated CNS syndromes without signs of inflammation in the elderly. <i>Neurology</i> , 2017, 89, 1471-1475.	1.5	97
123	Update on anti-N-methyl-D-aspartate receptor encephalitis in children and adolescents. <i>Current Opinion in Pediatrics</i> , 2010, 22, 739-744.	1.0	95
124	Movement disorders in paraneoplastic and autoimmune disease. <i>Current Opinion in Neurology</i> , 2011, 24, 346-353.	1.8	94
125	Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome. <i>Journal of Neuroinflammation</i> , 2016, 13, 226.	3.1	94
126	Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies. <i>Neurology</i> , 2020, 94, e2302-e2310.	1.5	94



#	ARTICLE	IF	CITATIONS
127	Serum IgG Antibodies Against the NR <sub>1</sub> Subunit of the NMDA Receptor Not Detected in Schizophrenia. <i>American Journal of Psychiatry</i> , 2012, 169, 1120-1121.	4.0	93
128	Cortactin autoantibodies in myasthenia gravis. <i>Autoimmunity Reviews</i> , 2014, 13, 1003-1007.	2.5	93
129	Hashimoto encephalopathy in the 21st century. <i>Neurology</i> , 2020, 94, e217-e224.	1.5	92
130	Use and Safety of Immunotherapeutic Management of N-Methyl-D-Aspartate Receptor Antibody Encephalitis. <i>JAMA Neurology</i> , 2021, 78, 1333.	4.5	91
131	Human Autoantibodies against the AMPA Receptor Subunit GluA2 Induce Receptor Reorganization and Memory Dysfunction. <i>Neuron</i> , 2018, 100, 91-105.e9.	3.8	90
132	Paraneoplastic syndromes of the spinal cord, nerve, and muscle. <i>Muscle and Nerve</i> , 2000, 23, 1800-1818.	1.0	88
133	Paraneoplastic syndromes of the peripheral nerves. <i>Current Opinion in Neurology</i> , 2005, 18, 598-603.	1.8	88
134	Autoimmune Encephalitis in Postpartum Psychosis. <i>American Journal of Psychiatry</i> , 2015, 172, 901-908.	4.0	88
135	Neuro-Ophthalmologic Manifestations of Paraneoplastic Syndromes. <i>Journal of Neuro-Ophthalmology</i> , 2008, 28, 58-68.	0.4	83
136	Anti-N-methyl-D-aspartate Receptor Encephalitis During Pregnancy. <i>Archives of Neurology</i> , 2010, 67, 884-7.	4.9	75
137	Association of Progressive Cerebellar Atrophy With Long-term Outcome in Patients With Anti-N-Methyl-D-Aspartate Receptor Encephalitis. <i>JAMA Neurology</i> , 2016, 73, 706.	4.5	74
138	NMDA Receptor Internalization by Autoantibodies: A Reversible Mechanism Underlying Psychosis?. <i>Trends in Neurosciences</i> , 2016, 39, 300-310.	4.2	73
139	Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1753-1759.	1.4	71
140	Mechanisms of Caspr2 antibodies in autoimmune encephalitis and neuromyotonia. <i>Annals of Neurology</i> , 2018, 83, 40-51.	2.8	71
141	Neuronal molecular mimicry in immune-mediated neurologic disease. <i>Annals of Neurology</i> , 1998, 44, 87-98.	2.8	70
142	Anti-N-methyl-D-aspartate receptor encephalitis: A newly recognized inflammatory brain disease in children. <i>Arthritis and Rheumatism</i> , 2011, 63, 2516-2522.	6.7	70
143	Paraneoplastic syndromes and autoimmune encephalitis. <i>Neurology: Clinical Practice</i> , 2012, 2, 215-223.	0.8	70
144	Antibody Repertoire in Paraneoplastic Cerebellar Degeneration and Small Cell Lung Cancer. <i>PLoS ONE</i> , 2013, 8, e60438.	1.1	70

#	ARTICLE	IF	CITATIONS
145	International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	70
146	Anti-NMDA-Receptor Encephalitis and Other Synaptic Autoimmune Disorders. Current Treatment Options in <i>Neurology</i> , 2011, 13, 324-332.	0.7	69
147	Cloning and characterization of a lambert-eaton myasthenic syndrome antigen. <i>Annals of Neurology</i> , 1993, 33, 113-120.	2.8	68
148	Epilepsy surgery in drug resistant temporal lobe epilepsy associated with neuronal antibodies. <i>Epilepsy Research</i> , 2017, 129, 101-105.	0.8	67
149	Persistent Intrathecal Antibody Synthesis 15 Years After Recovering From Anti-N-methyl-D-aspartate Receptor Encephalitis. <i>JAMA Neurology</i> , 2013, 70, 117.	4.5	66
150	Childhood Onset of Stiff-Man Syndrome. <i>JAMA Neurology</i> , 2013, 70, 1531.	4.5	65
151	Status epilepticus of inflammatory etiology. <i>Neurology</i> , 2015, 85, 464-470.	1.5	64
152	Sleep disorders in autoimmune encephalitis. <i>Lancet Neurology</i> , The, 2020, 19, 1010-1022.	4.9	64
153	Neuro-ophthalmology and paraneoplastic syndromes. <i>Current Opinion in Neurology</i> , 2004, 17, 3-8.	1.8	63
154	Aggressive Course in Encephalitis With Opsoclonus, Ataxia, Chorea, and Seizures. <i>JAMA Neurology</i> , 2014, 71, 620.	4.5	63
155	Autoimmunity, seizures, and status epilepticus. <i>Epilepsia</i> , 2013, 54, 46-49.	2.6	62
156	Antigenic and mechanistic characterization of anti-AMPA receptor encephalitis. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 180-189.	1.7	62
157	Sleep disorder, chorea, and dementia associated with IgLON5 antibodies. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e136.	3.1	62
158	Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and Morvan's syndrome. <i>Nature Clinical Practice Neurology</i> , 2007, 3, 405-410.	2.7	61
159	NMDA Receptor Autoantibodies in Autoimmune Encephalitis Cause a Subunit-Specific Nanoscale Redistribution of NMDA Receptors. <i>Cell Reports</i> , 2018, 23, 3759-3768.	2.9	61
160	Effects of IgLON5 Antibodies on Neuronal Cytoskeleton: A Link between Autoimmunity and Neurodegeneration. <i>Annals of Neurology</i> , 2020, 88, 1023-1027.	2.8	61
161	Clinical features, prognostic factors, and antibody effects in anti-mGluR1 encephalitis. <i>Neurology</i> , 2020, 95, e3012-e3025.	1.5	60
162	Determination of Neuronal Antibodies in Suspected and Definite Creutzfeldt-Jakob Disease. <i>JAMA Neurology</i> , 2014, 71, 74.	4.5	59

#	ARTICLE	IF	CITATIONS
163	Localization of the neuronal antigen recognized by anti-Tr antibodies from patients with paraneoplastic cerebellar degeneration and Hodgkin's disease in the rat nervous system. <i>Acta Neuropathologica</i> , 1998, 96, 1-7.	3.9	58
164	Neuronal Surface Antibody-Mediated Autoimmune Encephalitis. <i>Seminars in Neurology</i> , 2014, 34, 458-466.	0.5	57
165	P/Q-type voltage-gated calcium channel antibodies in paraneoplastic disorders of the central nervous system. , 1999, 22, 119-122.		56
166	Autoimmune Encephalitis. <i>European Neurological Review</i> , 2012, 8, 31.	0.5	56
167	TREATMENT-RESPONSIVE SUBACUTE LIMBIC ENCEPHALITIS AND NMDA RECEPTOR ANTIBODIES IN A MAN. <i>Neurology</i> , 2008, 70, 728-729.	1.5	55
168	Patient With Homer-3 Antibodies and Cerebellitis. <i>JAMA Neurology</i> , 2013, 70, 506.	4.5	55
169	HLA and microtubule-associated protein tau H1 haplotype associations in anti-IgLON5 disease. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, .	3.1	55
170	Paraneoplastic Sensory Neuronopathy and Spontaneous Regression of Small Cell Lung Cancer. <i>Canadian Journal of Neurological Sciences</i> , 2003, 30, 269-271.	0.3	54
171	Clinical significance of Kelch-like protein 11 antibodies. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	54
172	Clinical, Neuroimmunologic, and CSF Investigations in First Episode Psychosis. <i>Neurology</i> , 2021, 97, e61-e75.	1.5	54
173	Status epilepticus due to paraneoplastic and nonparaneoplastic encephalitides. <i>Epilepsia</i> , 2009, 50, 58-60.	2.6	53
174	Characterization of the sleep disorder of anti-IgLON5 disease. <i>Sleep</i> , 2019, 42, .	0.6	52
175	Adenylate kinase 5 autoimmunity in treatment refractory limbic encephalitis. <i>Journal of Neuroimmunology</i> , 2007, 186, 177-180.	1.1	51
176	A novel treatmentâ€ responsive encephalitis with frequent opsoclonus and teratoma. <i>Annals of Neurology</i> , 2014, 75, 435-441.	2.8	51
177	Prolonged Follow-up and CSF Antibody Titers in a Patient With Anti-NMDA Receptor Encephalitis. <i>Neurology</i> , 2011, 76, S64-6.	1.5	50
178	Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease. <i>Neurology</i> , 2021, 97, .	1.5	50
179	Diagnosis and Management of Paraneoplastic Neurologic Disorders. <i>Current Treatment Options in Oncology</i> , 2013, 14, 528-538.	1.3	49
180	Antibodies to Delta/Notch-like Epidermal Growth Factorâ€ Related Receptor in Patients With Anti-Tr, Paraneoplastic Cerebellar Degeneration, and Hodgkin Lymphoma. <i>JAMA Neurology</i> , 2014, 71, 1003.	4.5	49

#	ARTICLE	IF	CITATIONS
181	Clinical and Immunological Diversity of Limbic Encephalitis: A Model for Paraneoplastic Neurologic Disorders. <i>Hematology/Oncology Clinics of North America</i> , 2006, 20, 1319-1335.	0.9	48
182	Paraneoplastic neuropathies. <i>Current Opinion in Neurology</i> , 2013, 26, 489-495.	1.8	48
183	Sleep disorders in anti-NMDAR encephalitis. <i>Neurology</i> , 2020, 95, e671-e684.	1.5	47
184	ZIC antibodies in paraneoplastic cerebellar degeneration and small cell lung cancer. <i>Journal of Neuroimmunology</i> , 2008, 201-202, 163-165.	1.1	46
185	Isolated hemidystonia associated with NMDA receptor antibodies. <i>Movement Disorders</i> , 2011, 26, 351-352.	2.2	46
186	Limitations of a Commercial Assay as Diagnostic Test of Autoimmune Encephalitis. <i>Frontiers in Immunology</i> , 2021, 12, 691536.	2.2	46
187	Late-onset neuromyelitis optica spectrum disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, .	3.1	44
188	Mouse model of anti-NMDA receptor post-herpes simplex encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e529.	3.1	44
189	The neuronal nuclear antigen recognized by the human anti-Ri autoantibody is expressed in central but not peripheral nervous system neurons. <i>Neuroscience Letters</i> , 1993, 150, 212-214.	1.0	43
190	EFA6A-like antibodies in paraneoplastic encephalitis associated with immature ovarian teratoma: a case report. <i>Journal of Neuro-Oncology</i> , 2006, 81, 71-74.	1.4	43
191	Anti-Ri-associated paraneoplastic opsoclonus-ataxia syndrome in a man with transitional cell carcinoma. <i>Cancer</i> , 2001, 91, 1423-1428.	2.0	42
192	Paraneoplastic neurologic syndromes. <i>Neurologic Clinics</i> , 2003, 21, 221-247.	0.8	42
193	Intrathecal injection of P/Q type voltage-gated calcium channel antibodies from paraneoplastic cerebellar degeneration cause ataxia in mice. <i>Journal of Neuroimmunology</i> , 2013, 261, 53-59.	1.1	42
194	Clinical Neuropathology practice guide 4-2013: post-herpes simplex encephalitis: N-methyl-D-aspartate receptor antibodies are part of the problem. , 2013, 32, 251-254.		42
195	Paraneoplastic anti-Hu serum: studies on human tumor cell lines. <i>Journal of Neuroimmunology</i> , 1997, 79, 202-210.	1.1	41
196	Anti-Ma2-associated encephalitis with normal FDG-PET: a case of pseudo-Whipple's disease. <i>Nature Clinical Practice Neurology</i> , 2006, 2, 566-572.	2.7	41
197	Orthostatic myoclonus associated with Caspr2 antibodies. <i>Neurology</i> , 2016, 86, 1353-1355.	1.5	41
198	Paraneoplastic Neurologic Syndromes. <i>Neurologic Clinics</i> , 2018, 36, 675-685.	0.8	41

#	ARTICLE	IF	CITATIONS
199	Neuroimmune disorders of the central nervous system in children in the molecular era. <i>Nature Reviews Neurology</i> , 2018, 14, 433-445.	4.9	41
200	Paraneoplastic syndromes. <i>Current Opinion in Immunology</i> , 1997, 9, 723-729.	2.4	40
201	DEF-3(g16/NY-LU-12), an RNA binding protein from the 3p21.3 homozygous deletion region in SCLC. <i>Oncogene</i> , 1999, 18, 2589-2597.	2.6	40
202	Seizures as first symptom of anti-NMDA receptor encephalitis are more common in men. <i>Neurology</i> , 2014, 82, 550-551.	1.5	40
203	Paraneoplastic Neurologic Syndromes: Approaches to Diagnosis and Treatment. <i>Seminars in Neurology</i> , 2003, 23, 215-224.	0.5	39
204	Metastases to the peripheral nervous system. <i>Journal of Neuro-Oncology</i> , 2005, 75, 101-110.	1.4	39
205	Update on Paraneoplastic and Autoimmune Disorders of the Central Nervous System. <i>Seminars in Neurology</i> , 2010, 30, 320-331.	0.5	39
206	An Optimized Immunohistochemistry Technique Improves NMO-IgG Detection: Study Comparison with Cell-Based Assays. <i>PLoS ONE</i> , 2013, 8, e79083.	1.1	39
207	Encefalitis por anticuerpos contra el receptor de NMDA. <i>Medicina Clínica</i> , 2018, 151, 71-79.	0.3	39
208	Paraneoplastic cerebellar ataxia and antibodies to metabotropic glutamate receptor 2. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	39
209	Reduced serial dependence suggests deficits in synaptic potentiation in anti-NMDAR encephalitis and schizophrenia. <i>Nature Communications</i> , 2020, 11, 4250.	5.8	38
210	Association of anti-Yo (type I) antibody with paraneoplastic cerebellar degeneration in the setting of transitional cell carcinoma of the bladder: Detection of Yo antigen in tumor tissue and fall in antibody titers following tumor removal. <i>Annals of Neurology</i> , 1999, 45, 805-809.	2.8	37
211	Severe hypokinesia caused by paraneoplastic anti-Ma2 encephalitis associated with bilateral intratubular germ-cell neoplasm of the testes. <i>Movement Disorders</i> , 2007, 22, 728-731.	2.2	37
212	Prevalence and treatment of anti-NMDA receptor encephalitis – Authors' reply. <i>Lancet Neurology</i> , The, 2013, 12, 425-426.	4.9	37
213	Paraneoplastic neurological syndromes: diagnosis and treatment. <i>Current Opinion in Internal Medicine</i> , 2008, 7, 82-87.	1.5	36
214	Afferent facilitation of corticomotor responses is increased by IgGs of patients with NMDA-receptor antibodies. <i>Journal of Neurology</i> , 2011, 258, 27-33.	1.8	36
215	Paraneoplastic anti-NMDAR encephalitis: long term follow-up reveals persistent serum antibodies. <i>Journal of Neurology</i> , 2011, 258, 1568-1570.	1.8	36
216	Allosteric modulation of NMDA receptors prevents the antibody effects of patients with anti-NMDAR encephalitis. <i>Brain</i> , 2020, 143, 2709-2720.	3.7	36

#	ARTICLE	IF	CITATIONS
217	Seizure-related 6 homolog like 2 autoimmunity. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	36
218	Anti-Hu Immunolabeling as an Index of Neuronal Differentiation in Human Brain Tumors. <i>American Journal of Surgical Pathology</i> , 1998, 22, 195-200.	2.1	36
219	Paraneoplastic cerebellar degeneration: Yo-expressing tumor revealed after a 5-year follow-up with FDG-PET. <i>Journal of the Neurological Sciences</i> , 2006, 250, 153-155.	0.3	35
220	Serial brain 18FDG-PET in anti-AMPA receptor limbic encephalitis. <i>Journal of Neuroimmunology</i> , 2014, 271, 53-55.	1.1	35
221	Neuropathological Variability within a Spectrum of <sc>NMDAR</sc> Encephalitis. <i>Annals of Neurology</i> , 2021, 90, 725-737.	2.8	35
222	Clinical neuropathology practice guide 5-2012: Updated guideline for the diagnosis of antineuronal antibodies. , 2012, 31, 337-341.		34
223	The Photoreceptor Cell-Specific Nuclear Receptor is an Autoantigen of Paraneoplastic Retinopathy. <i>Journal of Neuro-Ophthalmology</i> , 2001, 21, 168-172.	0.4	33
224	Anti-GAD Antibody Positive Stiff-Limb Syndrome in Multiple Myeloma. <i>Journal of Neuro-Oncology</i> , 2003, 65, 173-175.	1.4	33
225	Antibodies to dendritic neuronal surface antigens in opsoclonus myoclonus ataxia syndrome. <i>Journal of Neuroimmunology</i> , 2015, 286, 86-92.	1.1	33
226	Paraneoplastic recurrent multifocal encephalitis presenting with epilepsy partialis continua. <i>Journal of Neuro-Oncology</i> , 2005, 72, 63-66.	1.4	32
227	Case 4-2007. <i>New England Journal of Medicine</i> , 2007, 356, 612-620.	13.9	32
228	Acute psychiatric illness in a young woman: an unusual form of encephalitis. <i>Medical Journal of Australia</i> , 2009, 191, 284-286.	0.8	32
229	Caspr2 autoantibodies target multiple epitopes. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e127.	3.1	32
230	When a serum test overrides the clinical assessment. <i>Neurology</i> , 2015, 84, 1379-1381.	1.5	32
231	Pseudo-Piano Playing Motions and Nocturnal Hypoventilation in Anti-NMDA Receptor Encephalitis: Response to Prompt Tumor Removal and Immunotherapy. <i>Internal Medicine</i> , 2011, 50, 627-630.	0.3	31
232	Antibodies to Nâ€methylâ€Dâ€aspartate and other synaptic receptors in choreoathetosis and relapsing symptoms postâ€herpes virus encephalitis. <i>Movement Disorders</i> , 2014, 29, 3-6.	2.2	31
233	<sc>NMDAR</sc> Antibodies Alter Dopamine Receptors and Cause Psychotic Behavior in Mice. <i>Annals of Neurology</i> , 2020, 88, 603-613.	2.8	31
234	The growing spectrum of antibody-associated inflammatory brain diseases in children. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e92.	3.1	30

#	ARTICLE	IF	CITATIONS
235	Pregnancy outcomes in anti-NMDA receptor encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	30
236	Clinical features of seronegative, but CSF antibody-positive, anti-NMDA receptor encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e659.	3.1	30
237	Current therapies for paraneoplastic neurologic syndromes. <i>Current Treatment Options in Neurology</i> , 2003, 5, 69-77.	0.7	29
238	Scleromyxedema and dermatomyositis neuro syndrome in a patient with multiple myeloma effectively treated with dexamethasone and bortezomib. <i>American Journal of Hematology</i> , 2011, 86, 893-896.	2.0	29
239	Reversible paraneoplastic encephalitis in three patients with ovarian neoplasms. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2012, 91, 630-634.	1.3	29
240	Acquired Neuromyotonia Heraldng Recurrent Thymoma in Myasthenia Gravis. <i>JAMA Neurology</i> , 2013, 70, 1311-4.	4.5	29
241	Carbonic anhydrase-related protein <sc>VIII</sc> antibodies and paraneoplastic cerebellar degeneration. <i>Neuropathology and Applied Neurobiology</i> , 2014, 40, 650-653.	1.8	29
242	Telemedicine assessment of long-term cognitive and functional status in anti-leucine-rich, glioma-inactivated 1 encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	29
243	Hu Immunolabeling as a Marker of Neural and Neuroendocrine Differentiation in Normal and Neoplastic Human Tissues: Assessment Using a Recombinant Anti-Hu Fab Fragment. <i>International Journal of Surgical Pathology</i> , 2000, 8, 109-117.	0.4	28
244	Paraneoplastic disorders of eye movements. <i>Annals of the New York Academy of Sciences</i> , 2011, 1233, 279-284.	1.8	28
245	Netrin-1 receptor antibodies in thymoma-associated neuromyotonia with myasthenia gravis. <i>Neurology</i> , 2017, 88, 1235-1242.	1.5	28
246	N-Methyl-D-Aspartate Receptor Antibodies in Autoimmune Encephalopathy Alter Oligodendrocyte Function. <i>Annals of Neurology</i> , 2020, 87, 670-676.	2.8	28
247	Thymoma and Autoimmune Encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	28
248	Small-cell carcinoma of the lung presenting with paraneoplastic peripheral nerve microvasculitis and optic neuropathy. , 1998, 21, 1358-1359.		27
249	Anti-NMDA-receptor encephalitis in a 3 year old patient with chromosome 6p21.32 microdeletion including the HLA cluster. <i>European Journal of Paediatric Neurology</i> , 2011, 15, 163-166.	0.7	27
250	Pitfalls in the detection of CV2 (CRMP5) antibodies. <i>Journal of Neuroimmunology</i> , 2016, 290, 80-83.	1.1	27
251	Comparison of Diagnostic Accuracy of Microscopy and Flow Cytometry in Evaluating N-Methyl-D-Aspartate Receptor Antibodies in Serum Using a Live Cell-Based Assay. <i>PLoS ONE</i> , 2015, 10, e0122037.	1.1	27
252	Caveats and Pitfalls of SOX1 Autoantibody Testing With a Commercial Line Blot Assay in Paraneoplastic Neurological Investigations. <i>Frontiers in Immunology</i> , 2019, 10, 769.	2.2	26



#	ARTICLE	IF	CITATIONS
253	Encephalitis with Autoantibodies against the Glutamate Kainate Receptors <scp>GluK2</scp>. Annals of Neurology, 2021, 90, 101-117.	2.8	26
254	Clinico-pathological correlation in adenylate kinase 5 autoimmune limbic encephalitis. Journal of Neuroimmunology, 2015, 287, 31-35.	1.1	25
255	Role of 18F-FDG-PET imaging in the diagnosis of autoimmune encephalitis – Authors' reply. Lancet Neurology, The, 2016, 15, 1010.	4.9	25
256	Neurofilament Light Chain Levels in Anti-NMDAR Encephalitis and Primary Psychiatric Psychosis. Neurology, 2022, 98, .	1.5	25
257	Anti-Hu antibodies in Merkel cell carcinoma. Annals of Neurology, 2002, 52, 111-115.	2.8	24
258	Anti-N-methyl-d-aspartate receptor encephalitis associated with carcinosarcoma with neuroendocrine differentiation of the uterus. Journal of Neurology, 2011, 258, 1351-1353.	1.8	24
259	Paraneoplastic Neurologic Disorders in Children. Current Neurology and Neuroscience Reports, 2011, 11, 187-194.	2.0	24
260	Anti-N-methyl-D-aspartate Receptor Encephalitis. Archives of Neurology, 2010, 67, 250-1.	4.9	24
261	Update on Paraneoplastic Neurologic Disorders. Oncologist, 2010, 15, 603-617.	1.9	23
262	Protein kinase C $\delta$ antibodies and paraneoplastic cerebellar degeneration. Journal of Neuroimmunology, 2013, 256, 91-93.	1.1	23
263	CNS autoimmunity: new findings and pending issues. Lancet Neurology, The, 2012, 11, 17-19.	4.9	22
264	Seizures and movement disorders: phenomenology, diagnostic challenges and therapeutic approaches. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 920-928.	0.9	22
265	A call for a global COVID-19 Neuro Research Coalition. Lancet Neurology, The, 2020, 19, 482-484.	4.9	22
266	Analysis of antibodies to surface epitopes of contactin-2 in multiple sclerosis. Journal of Neuroimmunology, 2012, 244, 103-106.	1.1	21
267	Neuropathologic features of anti-dipeptidyl-peptidase-like protein-6 antibody encephalitis. Neurology, 2015, 84, 430-432.	1.5	20
268	Clinical enigmas of paraneoplastic neurologic disorders. Clinical Neurology and Neurosurgery, 1995, 97, 61-70.	0.6	19
269	The MAZ protein is an autoantigen of Hodgkin's disease and paraneoplastic cerebellar dysfunction. Annals of Neurology, 2003, 53, 123-127.	2.8	19
270	Reduced N-acetylaspartate in the basal ganglia of a patient with anti-NMDA receptor encephalitis. Movement Disorders, 2009, 24, 784-786.	2.2	19



#	ARTICLE	IF	CITATIONS
271	Update on paraneoplastic neurologic disorders. <i>Community Oncology</i> , 2010, 7, 219-224.	0.2	18
272	Toll-like receptor 3 deficiency in autoimmune encephalitis post-herpes simplex encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e611.	3.1	18
273	Frequency and relevance of IgM, and IgA antibodies against MOG in MOG-IgG-associated disease. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 230-234.	0.9	18
274	p53 gene mutations in primary lung tumors are conserved in brain metastases. <i>Journal of Neuro-Oncology</i> , 1992, 14, 93-100.	1.4	17
275	Functional analysis of CD8+ T cell responses to the onconeural self protein cdr2 in patients with paraneoplastic cerebellar degeneration. <i>Journal of Neuroimmunology</i> , 2008, 193, 173-182.	1.1	17
276	Thymoma-associated paraneoplastic encephalitis (TAPE): Diagnosis and treatment of a potentially fatal condition. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2011, 141, e17-e20.	0.4	17
277	Clinical Reasoning: Agitation and psychosis in a patient after renal transplantation. <i>Neurology</i> , 2012, 79, e41-4.	1.5	17
278	Identification of adenylate kinase 5 antibodies during routine diagnostics in a tissue-based assay: Three new cases and a review of the literature. <i>Journal of Neuroimmunology</i> , 2019, 334, 576975.	1.1	17
279	Placental transfer of NMDAR antibodies causes reversible alterations in mice. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	17
280	Human CASPR2 Antibodies Reversibly Alter Memory and the CASPR2 Protein Complex. <i>Annals of Neurology</i> , 2022, 91, 801-813.	2.8	17
281	<scp>ZSCAN1</scp> Autoantibodies Are Associated with Pediatric Paraneoplastic <scp>ROHHAD</scp>. <i>Annals of Neurology</i> , 2022, 92, 279-291.	2.8	17
282	Normalization of the Tumor Marker CA-125 after Oophorectomy in a Patient with Paraneoplastic Cerebellar Degeneration without Detectable Cancer. <i>Gynecologic Oncology</i> , 1997, 65, 173-176.	0.6	16
283	Inverse Ocular Bobbing in a Patient With Encephalitis Associated With Antibodies to the N-methyl-D-aspartate Receptor. <i>Archives of Neurology</i> , 2008, 65, 1251.	4.9	15
284	Perfusion <sup>123</sup> IMPACT SPECT shows reversible abnormalities in GABA <sub>B</sub> receptor antibody associated encephalitis with normal MRI. <i>Brain and Behavior</i> , 2011, 1, 70-72.	1.0	15
285	Glazed (Vision) and Confused. <i>Survey of Ophthalmology</i> , 2010, 55, 169-173.	1.7	14
286	Case 34-2011. <i>New England Journal of Medicine</i> , 2011, 365, 1825-1833.	13.9	14
287	Cerebellar ataxia and autoantibodies restricted to glutamic acid decarboxylase 67 (GAD67). <i>Journal of Neuroimmunology</i> , 2016, 300, 15-17.	1.1	14
288	Neurological paraneoplastic syndromes. <i>Seminars in Immunopathology</i> , 1996, 18, 85-95.	4.0	13

#	ARTICLE	IF	CITATIONS
289	Paraneoplastic opsomyoclonus, cerebellar ataxia and encephalopathy associated with anti-Purkinje cell antibodies. <i>Journal of Neurology</i> , 1997, 244, 333-335.	1.8	13
290	A case of slow orthostatic tremor, responsive to intravenous immunoglobulin. <i>Movement Disorders</i> , 2011, 26, 1563-1565.	2.2	13
291	Chronic inflammatory demyelinating polyneuropathy associated with contactin-1 antibodies in a child. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, .	3.1	13
292	Considerations of psychotic symptomatology in anti-NMDA encephalitis: Similarity to cycloid psychosis. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 2456-2461.	0.2	13
293	Ung jente med psykose, kognitiv svikt og kramper. <i>Tidsskrift for Den Norske Laegeforening</i> , 2012, 132, 2073-2076.	0.2	13
294	Rituximab as potential therapy for paraneoplastic cerebellar degeneration in pediatric Hodgkin disease. <i>Pediatric Blood and Cancer</i> , 2012, 58, 986-987.	0.8	12
295	Hodgkin's lymphoma associated with paraneoplastic cerebellar degeneration in children: a case report and review of the literature. <i>Child's Nervous System</i> , 2017, 33, 509-512.	0.6	12
296	Anti-N-methyl D-Aspartate Receptor Encephalitis Mimics Viral Encephalitis. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 202-204.	1.1	11
297	Anti-N-methyl-D-aspartate glutamate receptor encephalitis presenting as paroxysmal exercise-induced foot weakness. <i>Movement Disorders</i> , 2013, 28, 820-822.	2.2	11
298	Encephalitis associated with antibodies against the NMDA receptor. <i>Medicina Clínica (English Edition)</i> , 2018, 151, 71-79.	0.1	11
299	Antibody of Unknown Significance (AUS): The Issue of Interpreting Antibody Test Results. <i>Movement Disorders</i> , 2021, 36, 1543-1547.	2.2	11
300	Current therapies for neuromuscular manifestations of paraneoplastic syndromes. <i>Current Neurology and Neuroscience Reports</i> , 2006, 6, 77-84.	2.0	10
301	Allosteric Modulation of NMDARs Reverses Patients' Autoantibody Effects in Mice. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	10
302	Do we need to measure specific antibodies in patients with limbic encephalitis?. <i>Neurology</i> , 2017, 88, 508-509.	1.5	9
303	Spatial Suppression and Sensitivity for Motion in Schizophrenia. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	0.9	9
304	Autoimmune encephalitis or autoimmune psychosis?. <i>European Neuropsychopharmacology</i> , 2021, 50, 112-114.	0.3	9
305	Absence of GluD2 Antibodies in Patients With Opsoclonus-Myoclonus Syndrome. <i>Neurology</i> , 2021, 96, e1082-e1087.	1.5	9
306	Human Metabotropic Glutamate Receptor 5 Antibodies Alter Receptor Levels and Behavior in Mice. <i>Annals of Neurology</i> , 2022, 92, 81-86.	2.8	9

#	ARTICLE	IF	CITATIONS
307	Recognizing Paraneoplastic Limbic Encephalitis. <i>Journal of Clinical Oncology</i> , 2009, 27, e230-e231.	0.8	8
308	Paraneoplastic neurologic disorders: a brief overview. <i>Memo - Magazine of European Medical Oncology</i> , 2012, 5, 197-200.	0.3	8
309	Recognizing autoimmune encephalitis as a cause of seizures. <i>Neurology</i> , 2019, 92, 877-878.	1.5	8
310	Paraneoplastic Syndromes and Progressive Motor Dysfunction. <i>Seminars in Neurology</i> , 1993, 13, 291-298.	0.5	7
311	Paraneoplastic limbic encephalitis associated with small-cell lung cancer. <i>Community Oncology</i> , 2007, 4, 491-494.	0.2	6
312	Paraneoplastic syndromes causing movement disorders. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2011, 100, 315-321.	1.0	6
313	Optic Neuritis in the Setting of NMDA Receptor Encephalitis. <i>Journal of Neuro-Ophthalmology</i> , 2014, 34, 316-319.	0.4	6
314	Characteristics of clinical relapses and patient-oriented long-term outcomes of patients with anti-N-methyl-d-aspartate receptor encephalitis. <i>Journal of Neurology</i> , 2022, 269, 2486-2492.	1.8	6
315	Antibody-mediated neuropsychiatric disorders. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 37-40.	1.5	6
316	[16] Characterization of neuronal antigens and antineuronal antibodies. <i>Methods in Neurosciences</i> , 1995, , 261-271.	0.5	5
317	Unusual neuro-ophthalmologic findings in a patient with anti-Yo-associated cerebellar degeneration. <i>Journal of the Neurological Sciences</i> , 2004, 225, 153-155.	0.3	5
318	Neuronal Antibodies in Creutzfeldt-Jakob Disease—Reply. <i>JAMA Neurology</i> , 2014, 71, 514.	4.5	5
319	Sleep disorder associated with antibodies to IgLON5: parasomnia or agrypnia?—Authors' reply. <i>Lancet Neurology</i> , The, 2014, 13, 864-865.	4.9	5
320	Anti-NMDA Receptor Encephalitis, Autoimmunity, and Psychosis. <i>Focus (American Psychiatric)</i> Tj ETQq0 0 0 rgBT /Overlock 1Q Tf 50 222	0.4	5
321	Precision in neuroimmunology. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e345.	3.1	5
322	The case for autoimmune neurology. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e373.	3.1	5
323	THE CLINICAL SPECTRM AND PATHOGENESIS OF PARANEOPLASTIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM. <i>Hematology/Oncology Clinics of North America</i> , 2001, 15, 1109-1128.	0.9	4
324	Neue serologische Marker zur Differentialdiagnose der Autoimmun-Enzephalitis/New serological markers for the differential diagnosis of autoimmune limbic encephalitis. <i>Laboratoriums Medizin</i> , 2011, 35, 329-342.	0.1	4

#	ARTICLE	IF	CITATIONS
325	Central nervous system paraneoplastic disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 105, 853-864.	1.0	4
326	Reversible limbic encephalitis with antibodies against the membranes of neurones of the hippocampus. BMJ Case Reports, 2009, 2009, bcr0720080509-bcr0720080509.	0.2	4
327	The E. Graeme Robertson Lecture. Journal of Clinical Neuroscience, 1996, 3, 8-15.	0.8	3
328	THYMOMA, MYASTHENIA GRAVIS, ENCEPHALITIS, AND A NOVEL ANTICYTOPLASMIC NEURONAL ANTIBODY. Neurology, 2007, 69, 1302-1303.	1.5	3
329	Laboratoriums Medizin, 2012, 35, --.	0.1	3
330	Autoimmunity. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e181.	3.1	3
331	Immunoproteomic studies on paediatric opsoclonus-myoclonus associated with neuroblastoma. Journal of Neuroimmunology, 2016, 297, 98-102.	1.1	3
332	Acute disseminated encephalomyelitis: A rare autoimmune complication of herpes simplex encephalitis in the adult. Clinical Neurology and Neurosurgery, 2018, 175, 47-49.	0.6	3
333	N2 year in review. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, e925.	3.1	3
334	Herpes simplex encephalitis in a patient with cancer. Journal of Neuro-Oncology, 2006, 78, 211-211.	1.4	2
335	Paraneoplastic disorders of the memory and cognition. , 2009, , 377-394.		2
336	Laparoscopic epilepsy surgery. Intensive Care Medicine, 2010, 36, 367-368.	3.9	2
337	Complement-mediated cytotoxicity of antibodies to the GABAB receptor â€“ Authors' reply. Lancet Neurology, The, 2010, 9, 343-344.	4.9	2
338	Observations on the evolving fields of neuroimmunology and neuroinflammation. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e67.	3.1	2
339	Opsoclonus-Myoclonus Syndrome in the Era of Neuronal Cell Surface Antibodiesâ€”Reply. JAMA Neurology, 2016, 73, 891.	4.5	2
340	Looks can be deceiving. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e461.	3.1	2
341	Blocking Placental Class G Immunoglobulin Transfer Prevents NMDA Receptor Antibody Effects in Newborn Mice. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, e1061.	3.1	2
342	Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. , 2001, 50, 339.		2

#	ARTICLE	IF	CITATIONS
343	Paraneoplastic disorders of the nervous system. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 53-67.	2.2	1
344	Paraneoplastic Syndromes of the Nervous System. , 2008, , 237-255.		1
345	Paraneoplastic disorders of the memory and cognition: clinical aspects and therapeutic approaches. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 89, 873-876.	1.0	1
346	A multimodality approach to reversible paraneoplastic encephalitis associated with ovarian teratomas. <i>Acta Oncologica</i> , 2009, 48, 1079-1082.	0.8	1
347	Name a brain protein, and an autoantibody shall be found!. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e159.	3.1	1
348	Identifying targets for diagnosis, prognosis, and treatment. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e87.	3.1	1
349	Reply to: N-Methyl-D-Aspartate Receptor Autoantibodies in Psychiatric Illness. <i>Biological Psychiatry</i> , 2016, 79, e63.	0.7	1
350	Author response: The clinical spectrum of Caspr2 antibody-associated disease. <i>Neurology</i> , 2017, 88, 333-334.	1.5	1
351	In vitro effects of a human monoclonal antibody against the N-methyl-d-aspartate receptor. <i>Brain</i> , 2017, 140, e9-e9.	3.7	1
352	Paraneoplastic Syndromes of the Nervous System as Complications of Cancer. , 2018, , 221-238.		1
353	N2 year in review and message from the editor to our reviewers. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e525.	3.1	1
354	Pregnancy, N-Methyl-D-Aspartate Receptor Antibodies, and Neuropsychiatric Diseases. <i>Annals of Neurology</i> , 2020, 87, 324-325.	2.8	1
355	A probable case of anti-NMDAR encephalitis from 1830. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	1
356	N2 in the time of COVID-19. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e858.	3.1	1
357	Paraneoplastic Neurologic Syndromes. , 2020, , 676-687.e5.		1
358	Letter by Dalmau Regarding Article, "Serum Anti-NMDA (N-Methyl-D-Aspartate)-Receptor Antibodies and Long-Term Clinical Outcome After Stroke (PROSCIS-B)" <i>Stroke</i> , 2020, 51, e28.	1.0	1
359	N2 year in review. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e644.	3.1	1
360	Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. , 1999, 45, 162.		1

#	ARTICLE	IF	CITATIONS
361	Paraneoplastic Syndromes of the Nervous System. , 2003, , 159-169.		1
362	Paraneoplastic Neurologic Syndromes. , 2008, , 767-778.		1
363	Cancer and the Nervous System. , 2012, , 1200-1210.		1
364	Author Response: Clinical, Neuroimmunologic, and CSF Investigations in First Episode Psychosis. Neurology, 2021, 97, 1010-1010.	1.5	1
365	Antibodies to Neural Cell Surface Antigens. , 2022, , 135-166.		1
366	Pathogenesis and Disease Mechanisms in Neuronal Antibody-Mediated Encephalitis. , 2022, , 42-106.		1
367	Importance, Definitions, History, Classification, and Frequency of the Autoimmune Encephalitides. , 2022, , 1-18.		1
368	Autoimmune Psychosis. , 2022, , 503-526.		1
369	Frequently Asked Questions on Autoimmune Encephalitis and Related Disorders. , 2022, , 630-655.		1
370	Psychiatric Manifestations of Autoimmune Encephalitis. , 2022, , 527-544.		1
371	Author Response: Clinical, Neuroimmunologic, and CSF Investigations in First Episode Psychosis. Neurology, 2022, 98, 906-906.	1.5	1
372	The use of paraffin-embedded tissue for detection of antineuronal antibodies. Acta Neuropathologica, 1997, 94, 300-301.	3.9	0
373	PARANEOPLASTIC DISORDERS OF THE NERVOUS SYSTEM. CONTINUUM Lifelong Learning in Neurology, 2005, 11, 69-92.	0.4	0
374	Paraneoplastic Disorders. Blue Books of Neurology, 2010, , 411-430.	0.1	0
375	Neurologic Complications of Cancer. Seminars in Neurology, 2010, 30, 215-216.	0.5	0
376	Paraneoplastic Neurological Disorders in Leukemia and Lymphoma. , 2012, , 329-344.		0
377	Anti-NMDA Receptor Encephalitis and Other Autoimmune and Paraneoplastic Movement Disorders. , 2013, , 289-303.		0
378	Paraneoplastic movement disorders. , 0, , 39-51.		0

#	ARTICLE	IF	CITATIONS
379	Reply. <i>Annals of Neurology</i> , 2014, 76, 464-465.	2.8	0
380	The first anniversary issue. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e137.	3.1	0
381	A box of chocolates. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e234.	3.1	0
382	Complex relationships. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e262.	3.1	0
383	An interesting variety. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e201.	3.1	0
384	Alphabet soup. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e217.	3.1	0
385	Importance of clinical observations. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e442.	3.1	0
386	Message from the Editor to our Reviewers. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e426.	3.1	0
387	Horizontal saccadic palsy as a prominent symptom of anti-NMDAR encephalitis. <i>Neurology: Clinical Practice</i> , 2019, 11, 10.1212/CPJ.0000000000000750.	0.8	0
388	“Time to recharge”. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	0
389	How DIRS is refining concepts. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e677.	3.1	0
390	Anti-NMDA Receptor Encephalitis and Other Autoimmune and Paraneoplastic Movement Disorders. <i>Current Clinical Neurology</i> , 2022, , 271-291.	0.1	0
391	Reply to: Comparing <sc>VUS</sc> and <sc>AUS</sc>: Parallels and Differences in Neurogenetics and Neuroimmunology. <i>Movement Disorders</i> , 2021, 36, 2454-2456.	2.2	0
392	Paraneoplastic Syndromes, <i>Central. , 2003, , 784-787.</i>		0
393	Paraneoplastic Syndromes, <i>Immunology. , 2003, , 787-790.</i>		0
394	Paraneoplastic Syndromes. , 2003, , 1146-1156.		0
395	Remote Effects of Cancer: Treatment of Paraneoplastic Neurologic Syndromes. , 2006, , 274-280.		0
396	Paraneoplastic Neurological Disorders. , 2007, , 163-169.		0

#	ARTICLE	IF	CITATIONS
397	Paraneoplastic Neurologic Syndromes. , 2007, , 517-533.		0
398	Paraneoplastic Neurologic Syndromes. , 2014, , 597-607.e4.		0
399	Transfer and Expression of Antioncogenes and Paraneoplastic Genes in Normal and Neoplastic Cells in Vitro and in Vivo. , 1995, , 275-VIII.		0
400	Neurological paraneoplastic syndromes. , 1996, , 203-213.		0
401	“The more we know” Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, .	3.1	0
402	Fat embolism showing restriction on diffusion sequence in brain magnetic resonance imaging. Arquivos De Neuro-Psiquiatria, 2016, 74, 597-598.	0.3	0
403	Autoimmune Cerebellar Ataxias. , 2022, , 342-367.		0
404	Anti-NMDAR Encephalitis. , 2022, , 210-254.		0
405	Autoimmune and Inflammatory Encephalopathies as Complications of Cancer. , 2022, , 430-459.		0
406	Anti-IgLON5 Disease. , 2022, , 411-429.		0
407	Autoimmune Brainstem Encephalitis. , 2022, , 368-390.		0
408	Deconstructing Hashimoto Encephalopathy. , 2022, , 460-475.		0
409	CNS Syndromes at the Frontier of Autoimmune Encephalitis. , 2022, , 476-502.		0
410	Acute Disseminated Encephalomyelitis and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. , 2022, , 290-314.		0
411	Autoimmune Dementia: A Useful Term?. , 2022, , 611-629.		0
412	Seizures and Antibodies Against Surface Antigens. , 2022, , 255-289.		0
413	Abnormal Movements in Neurological Autoimmune Disorders. , 2022, , 545-562.		0
414	Immunity, Inflammation, and Epilepsy. , 2022, , 588-610.		0



#	ARTICLE	IF	CITATIONS
415	Neuromyelitis Optica Spectrum Disorders and Glial Fibrillary Acidic Protein Autoimmunity. , 2022, , 315-341.		0
416	Sleep and Autoimmunity. , 2022, , 563-587.		0
417	Limbic Encephalitis. , 2022, , 167-190.		0
418	Autoimmunity Against Proteins Associated with Voltage-Gated Potassium Channels. , 2022, , 191-209.		0
419	Antibodies to Intracellular Antigens in CNS Disorders. , 2022, , 107-134.		0
420	Autoimmunity Against the Inhibitory Synapsis. , 2022, , 391-410.		0
421	General Approach to Diagnosis. , 2022, , 19-41.		0